DV
Dividend Vision

ADMA — ADMA Biologics, Inc.

ADMA Biologics, Inc. (ADMA)

Total return is 10.8% over the past 12.8 years, 445.4 points behind SPY at 456.2%. Its deepest 1-year drawdown was 62.7%.

ADMA Biologics is an equity stock focused on the biopharmaceutical sector, specifically in the development and commercialization of plasma-derived biologics and recombinant human therapeutic proteins. The company does not currently pay distributions and therefore offers no yield profile for income-focused investors. This stock appeals primarily to growth-oriented investors seeking exposure to specialized therapeutic markets rather than those pursuing dividend income strategies.

ADMA key facts

Asset type
Stock
Asset class
Equity
Inception date
10/17/2013
Distribution frequency
None
Last close
$9.47
Market cap
$2,121,134,848
Average volume
1308600.0
Beta
0.768
Payout ratio
0.0
P/E ratio
13.5286
Forward P/E
12.3457
EPS
$0.70